Detection of Graft Versus Host Disease With [18F]F-AraG
Detection of Graft Versus Host Disease With [18F]F-AraG, a Positron Emission Tomography Tracer for Activated T Cells
Sponsor: CellSight Technologies, Inc.
This PHASE1 trial investigates Graft Versus Host Disease and is currently completed. CellSight Technologies, Inc. leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
-
Nov 2024 — Jan 2026 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 8 earlier versions
-
Apr 2022 — Nov 2023 [monthly]
Recruiting PHASE1
-
Sep 2021 — Apr 2022 [monthly]
Recruiting PHASE1
-
Feb 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Aug 2019 — Aug 2020 [monthly]
Recruiting PHASE1
-
Jun 2018 — Aug 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CellSight Technologies, Inc.
- National Cancer Institute (NCI)
- Stanford University
For direct contact, visit the study record on ClinicalTrials.gov .